PHILADELPHIA — Actin is the most abundant protein in the body, and when you look more closely at its fundamental role in life, it’s easy to see why. It is the basis of most movement in the body, and all cells and components within them have the capacity to move: muscle contracting, heart beating, blood clotting, and nerve cells communicating, among many other functions. And, movement can turn harmful when cancer cells break away from tumors to set up shop in distant tissues.
Adding to the growing fundamental understanding of the machinery of muscle cells, a group of biophysicists from the Perelman School of Medicine at the University of Pennsylvania describe in the journal Science this week – in minute detail -- how actin filaments are stabilized at one of their ends to form a basic muscle structure called the sarcomere.
With the help of many other proteins, actin molecules polymerize to form filaments that give rise to structures of many different shapes. The actin filaments have a polarity, with a plus and minus end, reflecting their natural tendency to gain or lose subunits when not stabilized.
Actin is one of the two major proteins (together with myosin) that form the sarcomere -- the contractile structures of cardiac, skeletal, and smooth muscle cells. In sarcomeres, actin filaments are stabilized at both ends by capping proteins. At the minus end of the filament, the universal capping protein is tropomodulin.
“While the existence of this protein has been known for almost 30 years, we still did not know how it actually works,” says senior author Roberto Dominguez, PhD, professor of Physiology. His lab is dedicated to deciphering the fundamental mechanisms of proteins responsible for movement, and how these components fit together at the atomic level.
“We describe how tropomodulin interacts with the slow-growing end of actin filaments,” says coauthor Yadaiah Madasu, PhD, a postdoctoral fellow in the Dominquez lab. “From a clinical point of view, we know that mutations in tropomodulin can trigger an accumulation of irregular actin filament bundles, which contribute to nemaline myopathy or other skeletal muscle disorders typified by delayed motor development and muscle weakness.”
“The lack of structural information for the minus end of the actin filament severely limits our understanding of how tropomodulin caps actin,” says Dominguez. The team described atomic crystal structures of tropomodulin complexes with actin. The structures and biochemical analysis of engineered tropomodulin variants show how one tropomodulin molecule winds around the minus end of an actin filament, making highly specific interactions with three actin subunits and two tropomyosin molecules (another protein characteristic of muscle sarcomeres) on each side of the actin filament. The detailed picture emerging from this study will help shed light on how mutations in tropomodulin, actin, and tropomysin can cause heart disorders.
The team is now studying another muscle protein called leiomodin. It was discovered more recently and resembles tropomodulin, but appears to have a completely different function, by participating in the development and repair of muscle sarcomeres.
Postdoctoral fellow Nageswara Rao Jampani, PhD, was first author on the paper. The research was supported in part by the National Institute of General Medical Sciences (R01 GM073791). X-ray data collection at Beamline X6A of the National Synchrotron Light Source was supported by NIH grant GM-0080 and U.S. Department of Energy contract DE-AC02–98CH10886.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.